Statin treatment non-adherence and discontinuation: Clinical implications and potential solutions

Current Pharmaceutical Design

Volumn 20, Issue 40, 2014, Pages 6314-6324

  Phan, Kim ^a,b   Gomez, Yessica Haydee ^a,b   Elbaz, Laura ^a,b   Daskalopoulou, Stella S ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adherence; Cardiovascular disease; Cerebrovascular disease; Discontinuation; Interventions; Primary prevention; Risk assessment; Secondary prevention; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOLLOW UP; HEALTH PRACTITIONER; HOSPITALIZATION; HUMAN; MEDICATION COMPLIANCE; META ANALYSIS; PATIENT COMPLIANCE; PATIENT COUNSELING; PHARMACEUTICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SECONDARY PREVENTION; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; HUMANS; MEDICATION ADHERENCE; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICATION ADHERENCE;

EID: 84921513738     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140620162629     Document Type: Article

References (66)

1. [1] Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85-151.
2. [2] Mark DB, Van de Werf FJ, Simes RJ, et al. Cardiovascular disease on a global scale: defining the path forward for research and practice. Eur Heart J 2007; 28: 2678-84.
3. [3] Global status report on noncommunicable diseases 2010. Geneva, World Health Organization, 2011.
4. [4] Fondation des maladies du Coeur du Canada. (Fondation des maladies du Coeur du Canada). Le fardeau croissant des maladies cardiovasculaires et des accidents vasculaires cérébraux au Canada, 2003. Report No.: 1-89624-32-4.
5. [5] Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 1583-633.
6. [6] Lloyd-Jones DM, Wilson PW, Larson MG, et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med 2003; 163: 1966-72.
7. [7] Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
8. [8] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
9. [9] Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000; 102: 21-7.
10. [10] Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
11. [11] Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40.
12. [12] LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
13. [13] Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437-45.
14. [14] Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N Engl J Med 2008; 359: 2195-207.
15. [15] Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
16. [16] Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
17. [17] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
18. [18] Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008; 30: 2167-79.
19. [19] Deambrosis P, Saramin C, Terrazzani G, et al. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol 2007; 63: 197-203.
20. [20] Evans CD, Eurich DT, Lamb DA, et al. Retrospective observational assessment of statin adherence among subjects patronizing different types of community pharmacies in Canada. J Manag Care Pharm 2009; 15: 476-84.
21. [21] Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007; 21: 311-6.
22. [22] Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol 2009; 65: 1013-24.
23. [23] Poluzzi E, Strahinja P, Lanzoni M, et al. Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol 2008; 64: 425-32.
24. [24] Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009; 120: 28-34.
25. [25] Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacotherap 2010; 44: 1410-21.
26. [26] Gomez Sandoval YH, Braganza MV, Daskalopoulou SS. Statin discontinuation in high-risk patients: a systematic review of the evidence. Curr Pharm Des 2011; 17: 3669-89.
27. [27] Daskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE, Suissa S. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008; 29: 2083-91.
28. [28] Daskalopoulou SS, Doonan RJ, Delaney JA, Pilote L. Different Patterns of Statin Use in Patients with Acute Myocardial Infarction. Curr Vasc Pharmacol 2012 Sep 18. [Epub ahead of print]
29. [29] Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007; 10: 3-12.
30. [30] Corrao G, Scotti L, Zambon A, et al. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. Atherosclerosis 2011; 217: 479-85.
31. [31] Shalev V, Goldshtein I, Porath A, Weitzman D, Shemer J, Chodick G. Continuation of statin therapy and primary prevention of nonfatal cardiovascular events. Am J Cardiol 2012; 110: 1779-86.
32. [32] Dragomir A, Cote R, White M, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value in Health 2010; 13: 87-94.
33. [33] Rublee DA, Chen SY, Mardekian J, Wu N, Rao P, Boulanger L. Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy. Am J Therapeut 2012; 19: 24-32.
34. [34] Degli Esposti L, Saragoni S, Batacchi P, et al. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clinical Therapeut 2012; 34: 190-9.
35. [35] Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol 2011; 107: 1662-6.
36. [36] Poluzzi E, Piccinni C, Carta P, et al. Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. Eur J Clinical Pharmacol 2011; 67: 407-14.
37. [37] Haukka J, Niskanen L, Partonen T, Lonnqvist J, Tiihonen J. Statin usage and all-cause and disease-specific mortality in a nationwide study. Pharmacoepidemiol Drug Safety 2012; 21: 61-9.
38. [38] Ruokoniemi P, Korhonen MJ, Helin-Salmivaara A, et al. Statin adherence and the risk of major coronary events in patients with diabetes: A nested case-control study. Br J Clinical Pharmacol 2011; 71: 766-76.
39. [39] De Vera MA, Choi H, Abrahamowicz M, Kopec J, Goycochea-Robles MV, Lacaille D. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheumatic Diseases 2011; 70: 1020-4.
40. [40] De Vera MA, Choi H, Abrahamowicz M, Kopec J, Lacaille D. Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study. Arthritis Care Res 2012; 64: 809-16.
41. [41] Orlando A, Bar-Or D, Salottolo K, et al. Unintentional discontinuation of statins may increase mortality after traumatic brain injury in elderly patients: a preliminary observation. J Clinical Med Res 2013; 5: 168-73.
42. [42] Dowlatshahi D, Demchuk AM, Fang J, Kapral MK, Sharma M, Smith EE. Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage. Stroke 2012; 43: 1518-23.
43. [43] Brault M, Ray J, Gomez Y-H, Mantzoros CS, Daskalopoulou SS. Statin Treatment and New-onset Diabetes: a R 1 eview of Proposed Mechanisms. Metabolism. Forthcoming 2014.
44. [44] Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013.
45. [45] Axsom K, Berger JS, Schwartzbard AZ. Statins and diabetes: the good, the bad, and the unknown. Curr Atheroscler Rep 2013; 15: 299.
46. [46] Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.
47. [47] Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009; 25: 567-79.
48. [48] Humphreys JH, Warner A, Chipping J, et al. Mortality trends in patients with early rheumatoid arthritis over 20 years: Results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken) 2014.
49. [49] Maciejewski ML, Bryson CL, Perkins M, et al. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. Am J Managed Care 2010; 16: e20-34.
50. [50] Derose SF, Green K, Marrett E, et al. Automated Outreach to Increase Primary Adherence to Cholesterol-Lowering Medications. JAMA Int Med 2013; 173: 38-43.
51. [51] Liberman JN, Hutchins DS, Shrank WH, Slezak J, Brennan TA. Adherence to Medication Under Mandatory and Voluntary Mail Benefit Designs. Am J Managed Care 2011; 17: E260-9.
52. [52] Roshan F, Saeed M, Agewall S. Patients' self-estimated likelihood of taking a statin as prescribed after different types of prognostic information. Atherosclerosis 2010; 212: 586-8.
53. [53] Nieuwkerk PT, Nierman MC, Vissers MN, et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. Am J Cardiol 2012; 110: 666-72.
54. [54] Charland SL, Agatep BC, Epstein RS, et al. Patient knowledge of pharmacogenetic information improves adherence to statin therapy: Results of the additional KIF6 risk offers better adherence to statins (AKROBATS) trial. J Am College Cardiol 2012; 1: E1848.
55. [55] Casebeer L, Huber C, Bennett N, et al. Improving the physicianpatient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract 2009; 10: 48.
56. [56] Taitel M, Jiang J, Rudkin K, Ewing S, Duncan I. The impact of pharmacist face-to-face counseling to improve medication adherence among patients initiating statin therapy. Patient preference & adherence 2012; 6: 323-9.
57. [57] Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician followup and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007; 167: 847-52.
58. [58] Eussen SR, de Jong N, Rompelberg CJ, Garssen J, Verschuren WM, Klungel OH. Effects of the use of phytosterol/-stanolenriched margarines on adherence to statin therapy. Pharmacoepidemiol Drug Saf 2010; 19: 1225-32.
59. [59] Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004; 22 3: 13-23.
60. [60] Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: The UMPIRE randomized clinical trial. JAMA-J Am Medical Assoc 2013; 310: 918-29.
61. [61] Lafeber M, Spiering W, van der Graaf Y, et al. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. Am Heart J 2013; 166: 282-9.e1.
62. [62] Zeymer U, Junger C, Zahn R, et al. Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach. Curr Med Res Opinion 2011; 27: 1563-70.
63. [63] Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373: 1341-51.
64. [64] Bryant L, Martini N, Chan J, et al. Could the polypill improve adherence? The patient perspective. J Prim Health Care 2013; 5: 28-35.
65. [65] Goswami NJ, Dekoven M, Kuznik A, et al. Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial. Int J General Med 2013; 6: 647-55.
66. [66] Viswanathan M, Golin CE, Jones CD, et al. Closing the quality gap: revisiting the state of the science (vol. 4: medication adherence interventions: comparative effectiveness). Evid Rep Technol Assess (Full Rep) 2012: 1-685.